Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline dat ...

Core Insights - Enlivex Therapeutics Ltd. will participate in a live investor webinar discussing advancements in the treatment of inflammatory diseases, specifically focusing on knee osteoarthritis [1][2][7] Company Overview - Enlivex is a clinical-stage company specializing in macrophage reprogramming immunotherapy, developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune balance [8] Webinar Details - The webinar is scheduled for September 30, 2025, at 10:00 AM Eastern Time, featuring key opinion leaders in musculoskeletal disease and Enlivex's Vice Chairman [1][3] - The discussion will highlight positive Phase IIa topline data from the Allocetra™ program, showing significant pain reduction and functional improvement in patients with moderate-to-severe knee osteoarthritis [2][7] Expert Panel - The panel includes notable experts such as Professor Ali Mobasheri, Professor Philip Conaghan, Dr. Roger Pomerantz, and Jason Kolbert, each bringing extensive experience in musculoskeletal health and clinical research [3][4][5][6] Clinical Significance - The Phase IIa data from the Allocetra™ program indicates a strong potential to change the treatment landscape for knee osteoarthritis, a condition currently lacking approved disease-modifying therapies [2][7]

Core Insights - Allocetra™ has shown statistically significant and clinically meaningful improvements in pain and function for patients with knee osteoarthritis (KOA) in a Phase IIa trial [1][3][8] - The company plans to initiate a Phase IIb trial in Q2 2026, with six-month data from the ongoing Phase IIa trial expected in November 2025 [1][13][21] Company Overview - Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™ as a universal cell therapy [19] - The company aims to address the unmet medical needs of the aging population suffering from primary idiopathic KOA, which currently has limited treatment options [3][12] Clinical Trial Results - The Phase IIa trial (ENX-CL-05-001) demonstrated a 72% reduction in pain and a 109% improvement in function compared to the placebo group [13] - Allocetra™ achieved substantial improvements in a population of patients aged 60 and above, representing 54% of the study population [8][12] - The treatment was well tolerated, with no serious drug-related adverse events reported [11] Market Significance - KOA affects over 32 million Americans and is projected to impact 78 million by 2040, highlighting the urgent need for effective treatments [12][18] - The prevalence of KOA increases with age, with 30% of individuals over 60 years affected, emphasizing the potential market for Allocetra™ [12][18] Future Development Plans - Enlivex is advancing Allocetra™ toward late-stage development, with key milestones including the expected regulatory approval of the Phase IIb protocol in early 2026 [13][14] - The company is also exploring potential partnerships with larger firms interested in osteoarthritis treatments [15]

Core Insights - Enlivex Therapeutics announced positive topline data from the Phase IIa trial of Allocetra™, showing significant improvements in knee pain and function in patients with moderate-to-severe knee osteoarthritis [1][2][3] Group 1: Clinical Trial Results - In the modified intention-to-treat population, Allocetra™ demonstrated a 24% reduction in knee pain and a 26% improvement in knee function compared to placebo [1] - For age-related primary osteoarthritis patients, Allocetra™ resulted in a 72% reduction in knee pain and a 95% improvement in knee function compared to placebo, indicating a substantial and statistically significant effect [1][2] Group 2: Safety Profile - The trial reported a favorable safety profile for Allocetra™, with no severe adverse events and only mild to moderate, transient, and treatable side effects observed in most patients [2] Group 3: Company Overview - Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™ as a universal cell therapy aimed at reprogramming macrophages to restore immune balance [8] - The company emphasizes the significant unmet medical need in the knee osteoarthritis market, which affects over 32.5 million Americans and is projected to increase to 78 million by 2040 [6]

Core Insights - Enlivex Therapeutics Ltd. will host a webinar on August 18, 2025, to present 3-month topline results from the Phase IIa stage of its ENX-CL-05-001 trial evaluating Allocetra™ in patients with moderate to severe knee osteoarthritis [1][2] Company Overview - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune balance [5] Clinical Trial Details - The ongoing Phase IIa trial is a double-blind, randomized, placebo-controlled study assessing safety and efficacy, with endpoints measuring joint pain and function at 3, 6, and 12 months post-injection [4] - An interim analysis has been conducted to evaluate the potential benefits of expanding patient enrollment from 130 to 180, with 134 patients having completed the 3-month follow-up period [4][3] Osteoarthritis Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million people globally, with symptomatic knee osteoarthritis being particularly prevalent, impacting 40% of men and 47% of women in their lifetimes [3]

Company Overview - Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy, specifically developing Allocetra™, a universal, off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state [4]. Clinical Trial Details - The Phase I/II trial of Allocetra™ for moderate to severe knee osteoarthritis has completed follow-up for all 134 patients, with results expected to be publicly released by August 18, 2025 [1]. - The trial consists of two stages: a Phase I safety run-in to assess safety and tolerability, followed by a double-blind, randomized, placebo-controlled Phase IIa stage [2]. - Key efficacy endpoints include evaluating joint pain and function at three, six, and twelve months post-treatment, with an interim evaluation planned to assess the potential addition of up to 50 patients to the study [2]. Osteoarthritis Context - Osteoarthritis is the most common form of arthritis, affecting over 32.5 million Americans and more than 300 million people globally, with projections indicating that 78 million Americans will have osteoarthritis by 2040 [3]. - The condition leads to significant disability, with 40% of men and 47% of women developing knee osteoarthritis in their lifetimes, resulting in over one million hospitalizations annually in the U.S. [3]. - Currently, there are no FDA or EMA approved medications that can halt or reverse the progression of structural damage in joints affected by osteoarthritis [3].

Core Insights - Enlivex Therapeutics Ltd. will present data on its macrophage reprogramming therapy, Allocetra™, at the EULAR European Congress of Rheumatology in Barcelona from June 11-14, 2025 [1][2] - Allocetra™ aims to treat knee osteoarthritis by reprogramming macrophages to promote immune balance and reduce chronic inflammation, showing promising results in Phase I/II trials [2][4] Company Overview - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, with Allocetra™ being a universal, off-the-shelf cell therapy [4] - The therapy is designed to reset non-homeostatic macrophages to a homeostatic state, which is essential for immune system rebalancing [4] Clinical Study Details - The ongoing clinical study of Allocetra™ involves patients with moderate to severe knee osteoarthritis, with all patients enrolled in the Phase II stage of the trial [2] - The company anticipates topline data from the Phase II stage to be available by August 2025 [2] Presentation Information - The poster presentation titled "Phase I/II Trial of Allocetra™ Cell Therapy for Knee Osteoarthritis: Clinical Evidence of Response to Modulation of Inflammation" will be presented by Dr. Oren Hershkovitz and Einat Galamidi at the conference [3][6]

Core Insights - Enlivex Therapeutics Ltd. has been selected to present at the Israeli BioMed 2025 Conference, focusing on its macrophage reprogramming therapy, Allocetra™, for treating inflammatory diseases [1][2] Company Overview - Enlivex is a clinical-stage company specializing in macrophage reprogramming immunotherapy, developing Allocetra™, a universal, off-the-shelf cell therapy aimed at resetting macrophages to their homeostatic state [4] Product Details - Allocetra™ is designed to address non-homeostatic macrophages, which are linked to various chronic and life-threatening diseases, by reprogramming them to restore immune balance [2][4] - The company is advancing a clinical pipeline that includes multiple Phase I/II trials for conditions such as osteoarthritis and psoriatic arthritis [3] Clinical Trial Results - Recent interim data from a six-month study in moderate knee osteoarthritis indicated a 47% reduction in pain, a 46% improvement in joint function, and a 40% decrease in stiffness [3]

Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 World Congress on Osteoarthritis, taking place April 24-27, 2025, in Incheon (Seoul), South Korea. "These presentations at OARSI 2025 will highlight the growing body of evidence supporting Allocetra'sTM potentia ...

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage. Oren Hershkovitz, Ph.D, CEO of Enlivex, comm ...